The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
about
Clinical use of alprostadil topical cream in patients with erectile dysfunction: a reviewConformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and SildenafilAlprostadil cream in the treatment of erectile dysfunction: clinical evidence and experienceEvidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasiaPharmacogenetics of erectile dysfunction: navigating into uncharted watersLongitudinal evaluation of sexual function in a male cohort: the Olmsted county study of urinary symptoms and health status among men.Avanafil for erectile dysfunction.Safety of sildenafil in infants*.Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.The use of phosphodiesterase 5 inhibitors with concomitant medications.ADMET considerations for phosphodiesterase-5 inhibitors.Penile rehabilitation after radical prostatectomy: what the evidence really says.Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Avanafil - a further step to tailoring patient needs and expectations.A randomized double blinded placebo controlled trial of sildenafil for renoprotection prior to hilar clamping in patients undergoing robotic assisted laparoscopic partial nephrectomy.Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment.Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy.Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study.Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil.Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments.Sublingual Administration of Sildenafil Oro-dispersible Film: New Profiles of Drug Tolerability and Pharmacokinetics for PDE5 Inhibitors.High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.
P2860
Q26740510-25C36AAC-7342-498C-80DE-D9A89455B541Q27648887-6B69D5D6-509A-490F-923E-17871DF126E8Q28071503-AD7B11F4-D718-4870-8876-7FC8FACECE9CQ28077954-67CB8CF9-428C-4C7A-934D-C20F611966DBQ28249515-61CBCA39-E6B8-450F-AA60-70C28F9622AFQ33822355-AC9512AD-669E-4805-86DF-0F091A2B13A7Q34039001-6936DE29-5973-4B81-A227-CAB46893DB28Q35105255-D0F93110-82F1-4C0D-A68F-179DB58042D8Q37038183-B5C71C9C-225B-4302-98E5-037D940C556DQ37321940-748ACC7A-38B5-4FA1-A5E8-B3D523F45FA8Q38024409-550ADEB3-41DE-43A6-8ACF-851FE85B2881Q38119268-CC8727C6-D385-49F3-B146-2701DDE25FABQ38166600-02E1D033-4A23-4C4A-91D0-3A5C79589008Q38368957-A3DD337A-39E2-43DD-BA57-63597F52A66EQ38591731-44FB8575-4A27-408A-83ED-C506C82CE64DQ38763608-9CF46AE7-E38C-4714-9781-949B8F94B72EQ38815890-965D10A3-5523-41F9-9D0C-AACACF7FA80AQ38846047-EDFBE51A-F52E-4EE3-B52C-530621F5B4AEQ38950658-8549D98C-10C3-431F-AE34-C55A605563D2Q39846256-9B3F8674-6BFA-4508-9F7D-76C23BF9D379Q41951810-BDFE81C5-9F11-45F0-B3CD-01BAC6D8ABC2Q42509283-3E12E919-24E7-448B-B9FD-CEE392CBF60CQ42633722-819DA6B7-C49D-4E38-BC2E-EE21DB8E16E7Q44529978-5DA9D0D4-C3AA-49DE-9873-567506AC28DEQ49330212-5AC8D0DE-2544-4BD6-BE7B-31B273F62FC1Q50286858-135321A1-43D4-426A-9FC2-C6CE735C960CQ50793400-48F0FC50-B7C6-4993-AB0F-48997EE18485
P2860
The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The role of pharmacokinetics a ...... iesterase-5 inhibitor therapy.
@ast
The role of pharmacokinetics a ...... iesterase-5 inhibitor therapy.
@en
type
label
The role of pharmacokinetics a ...... iesterase-5 inhibitor therapy.
@ast
The role of pharmacokinetics a ...... iesterase-5 inhibitor therapy.
@en
prefLabel
The role of pharmacokinetics a ...... iesterase-5 inhibitor therapy.
@ast
The role of pharmacokinetics a ...... iesterase-5 inhibitor therapy.
@en
P2093
P2860
P356
P1476
The role of pharmacokinetics a ...... diesterase-5 inhibitor therapy
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.IJIR.3901522
P577
2006-09-21T00:00:00Z